In UICC stage III tumours, SATB2-low/absent showed significantly shortened survival characteristics (OS: 70.3 months vs. 84.4 months, p = 0.025; DSS: 74.5 months vs. 91 months, p = 0.012; DFS: 62.1 months vs. 81.2 months; p = 0.004) (Table S4) in all survival comparisons. The gene discussed is SATB2; the disease is neoplasm.